Fig. 4: KPT-330-inactivated cap-dependent translation initiation is dispensable for Mcl-1 downregulation. | Cell Death & Disease

Fig. 4: KPT-330-inactivated cap-dependent translation initiation is dispensable for Mcl-1 downregulation.

From: XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

Fig. 4

a The cap-binding assay in U87, U251, H1299, and A549 cells treated with indicated dose of KPT-330 for 48 h. b, c Western blot of indicated proteins in U87, U251, H1299, and A549 cells treated with KPT-330 (1 μM) for 48 h. c Proteins in mTOR complex in cell lysates as in b were immunoprecipitated followed by western blot. d Western blot of indicated proteins in U251 and H1299 cells treated with KPT-330 (1 μM) for indicated time periods. e The cap-binding assay in sh4E-BP1 and/or eIF4E H1299 cells treated as in a. f H1299 cells expressing sh4E-BP1 were treated with KPT-330 (1 μM) for 24 h and further with A-1331852 (1 μM) for 24 h, then subjected to flow cytometry analysis for the sub-G1 phase (mean ± SD, n = 3). *P < 0.05. g The bicistronic luciferase reporter assay in U251 and H1299 cells treated with KPT-330 (1 μM) for 24 h (mean ± SEM, n = 3). *P < 0.05. GAPDH was used as the loading control

Back to article page